title: Cerebrolysin reverses hippocampal neural atrophy in a mice model of diabetes mellitus type 1.
abstract: The animal model of streptozotocin-induced diabetes mellitus type 1 (DM1) is used to study neuronal and behavioral changes produced by an increase in blood-glucose levels. Our previous report showed that chronic streptozotocin administration induced atrophy of dendritic morphology of pyramidal neurons of the CA1 dorsal hippocampus. In addition, we showed that Cerebrolysin (Cbl), a neurotrophic peptide mixture, reduces the dendritic atrophy in animal models of aging. This study aimed to determine whether Cbl was capable of reducing behavioral and neuronal alterations, after 6 weeks of hyperglycemia in mice (streptozotocin-induced DM1). The levels of glucose in the blood were evaluated before and after streptozotocin administration and only animals with more than 240 mg/dL of blood-levels of glucose were used. After streptozotocin treatment, the mice received 6 weeks of Cbl, locomotor activity was measured and dendritic morphological changes were evaluated using Golgi-Cox stain procedure, and analyzed by the Sholl method. In mice treated with streptozotocin there was a clear reduction in the dendritic length of pyramidal neurons of the CA1 and granular cells of the dental gyrus of the dorsal hippocampus. Interestingly, Cbl reversed the morphological changes induced by streptozotocin. Our results extend the list of abnormal morphological changes detected in this model of DM, and support the possibility that Cbl may have beneficial effects in the management of brain alterations induced by DM.
authors: Laboratorio De Neuropsiquiatría, Instituto De Fisiología, Universidad Autónoma De Puebla, Puebla, México.
authors: Lizzette
authors: L
authors: Sanchez-Vega
authors: Ismael
authors: I
authors: Juárez
authors: Maria De Jesus
authors: Mde J
authors: Gomez-Villalobos
authors: Gonzalo
authors: G
authors: Flores
mesh_terms: D000596:Amino Acids / Q000494:pharmacology*; D000818:Animals; D001284:Atrophy / Q000188:drug therapy; D001786:Blood Glucose; D003712:Dendrites / Q000187:drug effects / Q000473:pathology; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000473:pathology*; D003922:Diabetes Mellitus, Type 1; D006624:Hippocampus / Q000187:drug effects* / Q000473:pathology*; D008124:Locomotion / Q000187:drug effects; D008297:Male; D051379:Mice; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology*
chemical_list: D000596:Amino Acids; D001786:Blood Glucose; D018696:Neuroprotective Agents; C006952:cerebrolysin
keywords: CA1; dentate gyrus; diabetes mellitus type 1; dorsal hippocampus; streptozotocin